Search

everythinglearnresearchcommunity

for

Search:↓

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Triamcinolone acetonide is more effective than cryotherapy for hair regrowth in alopecia areata but has different side effects.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Tofacitinib is a promising treatment for children with rheumatic diseases.

CTP-543 is generally safe for treating alopecia areata.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.

Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.

The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.

Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.

Triamcinolone acetonide injections effectively treat skin disorders like eczema and psoriasis.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.

Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.

Pimecrolimus boosts melanin production and movement of skin pigment cells.

Triamcinolone acetonide injections help regrow hair in alopecia areata patients.

Cyclosporine is more effective than betamethasone for treating alopecia areata, despite mild side effects.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Enhancing Tregs can protect against alopecia areata.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.